logo
banner

Journals & Publications

Journals Publications Papers

Papers

Near-Infrared Light-Responsive Nanoparticles with Thermosensitive Yolk-Shell Structure for Multimodal Imaging and Chemo-Photothermal Therapy of Tumor
Jul 13, 2017Author:
PrintText Size A A

Title: Near-infrared light-responsive nanoparticles with thermosensitive yolk-shell structure for multimodal imaging and chemo-photothermal therapy of tumor

 Authors: Shen, S; Ding, B; Zhang, SC; Qi, XY; Wang, K; Tian, J; Yan, YS; Ge, YR; Wu, L

 Author Full Names: Shen, Song; Ding, Bei; Zhang, Shengchang; Qi, Xueyong; Wang, Kun; Tian, Jie; Yan, Yongsheng; Ge, Yanru; Wu, Lin

 Source: NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 13 (5):1607-1616; 10.1016/j.nano.2017.02.014 JUL 2017

 Language: English

 Abstract: Thermosensitive yolk-shell nanoparticles were developed as remote-controlled targeting drug delivery platform for multimodal imaging and combined therapy of cancer. The nanoparticles were fabricated using magnetic Fe3O4 nanoparticles as photothermal cores, thermo-responsive poly(N-isopropylacrylamide)-co-1-Vinyl-2-pyrrolidone p(NIPAM-co-NVP) as shells (Fe3O4-PNIPAM), with a hollow space between the two layers for loading of chemotherapeutic drug. The magnetic iron oxide nanoparticle cores could absorb and transform light to heat efficiently upon the irradiation of near infrared (NIR) laser, resulting in the shrink of the PNIPAM shell and the release of chemo-drugs. In vivo fluorescence/photoacoustic images demonstrated that Fe3O4-PNIPAM nanoparticles could accumulate in the tumor after intravenous injection. Upon the irradiation of the NIR laser, DOX-Fe3O4-PNIPAM nanoparticles exhibited outstanding synergistic effect. The tumor inhibition rate increased from 40.3% (DOX-Fe3O4-PNIPAM alone) and 65.2% (Fe3O4-PNIPAM +NIR) to 91.5%. The results demonstrated that the NIR-responsive nanocarrier offers a novel strategy for cancer theranostics and combined therapy of cancer. (C) 2017 Elsevier Inc. All rights reserved.

 ISSN: 1549-9634

 eISSN: 1549-9642

 IDS Number: EY0QG

 Unique ID: WOS:000403662500003

 PubMed ID: 28285157

*Click Here to View Full Record